Clinical trialPhase 1Withdrawn
Tolfenamic Acid, Gemcitabine and Radiation for Locally Advanced or Metastatic Pancreatic Cancer Requiring Radiation
09.017 - A Phase I Study of Tolfenamic Acid With Gemcitabine and Radiation in Patients With Locally Advanced or Metastatic Pancreatic Cancer Requiring Definitive or Palliative Radiation Therapy
- Outcome
- Stopped earlyThe study closed prior to enrolling any participants. (Enrollment)
- Phase
- Phase 1
- Status
- Withdrawn
- Study type
- Interventional
- Start
- March 2014
- Expected end
- December 2019
- Enrollment
- 0 participants
- Sites
- 1
- Primary outcomes
- Evaluate safety and toxicity
- Sponsor
- Other
- Results posted
- No
- Last update
- 28 April 2015
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Papers 3
- BackgroundConcomitant chemoradiotherapy with low-dose weekly gemcitabine for nonmetastatic unresectable pancreatic cancer. DOI 10.4318/tjg.2011.0158↗
- BackgroundNew response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). DOI 10.1016/j.ejca.2008.10.026↗
- BackgroundPreoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. DOI 10.1200/jco.2007.15.8634↗